Bactericidal activity of cefodizime on Enterobacteriaceae in an in-vitro model simulating plasma pharmacokinetics in humans.
An in-vitro dialysis model was employed to assess the feasibility of once-daily dosing of cefodizime in the treatment of infections caused by various Enterobacteriaceae: Escherichia coli, Klebsiella pneumoniae, Morganella morganii, Serratia marcescens, Providencia stuartii and Enterobacter cloacae. This model simulated the concentrations of cefodizime detected in human blood after an intravenous (i.v.) bolus injection of 1 g or 2 g of the antibiotic. Validation of the model was undertaken to confirm its utility. Based on the data obtained with this model, once-daily dosing with 1 g cefodizime (i.v.) should be effective against infections due to the commonest Gram-negative bacteria (E. coli, K. pneumoniae, M. morganii). For infections caused by Enterobacteriaceae strains that produce large quantities of Class I beta-lactamases, twice-daily (P. stuartii or S. marcescens) or four times daily (E. cloacae) administration of 1 g cefodizime may be required.
Péchinot
A
A
Laboratoire de Bactériologie, Hôpital Universitaire du Bocage, Dijon,France.
Neuwirth
C
C
Bryskier
A
A
Duez
J M
JM
Kazmierczak
A
A
D002439:Cefotaxime / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000494:pharmacology; D002511:Cephalosporins / Q000494:pharmacology*; D004755:Enterobacteriaceae / Q000187:drug effects*; D006801:Humans; D008826:Microbial Sensitivity Tests; D008954:Models, Biological
D002511:Cephalosporins; D002439:Cefotaxime; C033356:cefodizime